Merck earnings top estimates amid solid demand for Keytruda cancer drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Leerink Partners Reiterates Outperform Rating on Merck (MRK)
November 1, 2024 7:20 AM EDTLeerink Partners analyst Joseph P. Schwartz reiterated an Outperform rating on Merck (NYSE: MRK).
The analyst comments "Bottom Line: Gardasil remained the primary topic for Merck (MRK, OP) earnings and continues to weigh on the stock, which is trading at a 13.6 PE multiple, below most of its... More
